3-(三氟甲基)苯硫脲 | 13114-87-9

• 物质功能分类: 有机原料 - 含氮基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(三氟甲基)苯硫脲
• 中文别名: 1-(3-(三氟甲基)苯基)脲
• 英文名称: N-(3-trifluoromethylphenyl)urea
• 英文别名: 1-(3-(trifluoromethyl)phenyl)urea；3-(trifluoromethyl)phenylurea；[3-(Trifluoromethyl)phenyl]urea
• CAS: 13114-87-9
• 化学式: C₈H₇F₃N₂O
• mdl: MFCD00025424
• 分子量: 204.152
• InChiKey: FQEIBEOBXKJAMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  101-103
• 沸点：
  237.0±40.0 °C(Predicted)
• 密度：
  1.425±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  T
• 海关编码：
  2924299090
• 储存条件：
  存放于室温、干燥且密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-[3-(Trifluoromethyl)phenyl]urea
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-[3-(Trifluoromethyl)phenyl]urea
CAS number: 13114-87-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7F3N2O
Molecular weight: 204.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(三氟甲基)苯硫脲 在 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 36.0h， 生成 (4R)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid
  参考文献：
  名称：

  冻结生物活性构象以增强效能：BAY 85-8501的鉴定，BAY 85-8501是人类中性粒细胞弹性蛋白酶对肺部疾病的选择性和强效抑制剂

  摘要：

  Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors

  DOI：

  10.1002/cmdc.201500131
• 作为产物：
  描述：

  3-三氟甲基苯甲酸 在 4-二甲氨基吡啶 、 ammonium hydroxide 、 sodium azide 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 0.08h， 生成 3-(三氟甲基)苯硫脲
  参考文献：
  名称：

  在一锅法利用Curtius重排中将羧酸直接转化为各种含氮化合物

  摘要：

  在本文中，我们报告了使用常规合成方法将灭活的羧酸单锅多步转化为各种含N的化合物的过程。发达的方法论使用羧酸作为伯胺的直接替代品，利用库尔蒂斯（Curtius）反应合成伯脲，仲/叔脲，O / S-氨基甲酸酯，苯甲酰脲，酰胺和N-甲酰基。基于亲核试剂的选择，该方法具有提供从单一羧酸开始提供多样化的含N化合物库的潜力。

  DOI：

  10.1021/acs.joc.9b01697
• 作为试剂：
  描述：

  2-甲砜基-4-氰基苯甲醛 、 3-(三氟甲基)苯硫脲 在 3-(三氟甲基)苯硫脲 作用下， 以64的产率得到allyl 4-[4-cyano-2-(methylsulfonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  参考文献：
  名称：

  ChemMedChem. 2015, 10, 1163-1173

  摘要：

  DOI：

文献信息

• [EN] DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ENRICHIS EN DEUTÉRIUM EN TANT QU'INHIBITEURS DE KINASES
  申请人：ASCEPION PHARMACEUTICALS INC

  公开号：WO2012028106A1

  公开（公告）日：2012-03-08

  The present invention provides deuterium-enriched heteroaryl-containing urea compounds (I) and use of the same for treating conditions mediated by protein kinase such as

  本发明提供了富含氘的杂环基脲化合物（I）以及利用这些化合物治疗由蛋白激酶介导的疾病的方法。
• METHOD FOR PRODUCING (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDINE-5-CARBONITRILE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180072685A1

  公开（公告）日：2018-03-15

  The present invention concerns a new and improved method for preparation of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile of formula (I), as well as the preparation and use of the crystal form (A) of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile of formula (I).

  本发明涉及一种用于制备式(I)的(4S)-4-[4-氰基-2-(甲磺基)苯基]-3,6-二甲基-2-氧代-1-[3-(三氟甲基)苯基]-1,2,3,4-四氢嘧啶-5-碳腈的新型改进方法，以及制备和使用式(I)的(4S)-4-[4-氰基-2-(甲磺基)苯基]-3,6-二甲基-2-氧代-1-[3-(三氟甲基)苯基]-1,2,3,4-四氢嘧啶-5-碳腈的晶型(A)。
• [EN] SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY<br/>[FR] DIHYDROPYRIMIDINONES BICYCLIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'ACTIVITÉ ÉLASTASE DE NEUTROPHILES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014135414A1

  公开（公告）日：2014-09-12

  This invention relates to substituted bicyclic dihydropyrimidinones of formula (1) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及式（1）的取代双环二氢嘧啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
  申请人：——

  公开号：US20020120011A1

  公开（公告）日：2002-08-29

  The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound: 1

  这项发明涉及替代多环芳基和杂环芳基的三级杂烷基胺化合物，可用作胆固醇酯转移蛋白（CETP；血浆脂质转移蛋白-I）的抑制剂，以及用于治疗动脉粥样硬化和其他冠状动脉疾病的化合物、组合物和方法。首选的三级杂烷基胺化合物是取代的N,N-二取代二胺。首选的具体N,N-二取代二胺化合物是：1
• [EN] PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES<br/>[FR] DERIVES DE PYRIMIDINONE UTILISES COMME AGENTS THERAPEUTIQUES CONTRE DES PROCESSUS INFLAMMATOIRES, ISCHEMIQUES ET DE REMODELAGE AIGUS ET CHRONIQUES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004024700A1

  公开（公告）日：2004-03-25

  The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases.

  这项发明涉及新颖的杂环衍生物，其制备方法以及它们在药物中的应用，特别是用于慢性阻塞性肺疾病的治疗。